Seres Therapeutics (MCRB) Misses Q3 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Seres Therapeutics (MCRB) PT Lowered to $16 at Oppenheimer
November 9, 2018 8:57 AM ESTOppenheimer analyst Mark Breidenbach lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $16.00 (from $17.00) while maintaining a Outperform rating.
The analyst commented, "Thursday, Seres reported 3Q results and reviewed recent progress. With the appointment of a new CMO, we see... More
